搜索推理链：对文献推理过程进行召回

{
    "code": 0,
    "data": {
        "reasoning_chains": [
            {
                "chain_id": "811894248839315456_4",
                "paper_id": "811894248839315456",
                "score": 0.030158730158730156,
                "paper": {
                    "id": "811894248839315456",
                    "doi": "10.1016/j.tins.2008.09.010",
                    "publication_id": "6770",
                    "publication_name": "Trends in Neurosciences _ Trends in Neurosciences",
                    "zh_title": "注意力缺陷多动障碍的多巴胺能假说需要重新审视",
                    "en_title": "The dopaminergic hypothesis of attention-deficit/hyperactivity disorder needs re-examining",
                    "authors": "Francois Gonon",
                    "publication_date": "2009-1",
                    "available_online": "",
                    "cover_date_start": "2009-01-01",
                    "area": "Medicine, Psychology, Biological Psychology",
                    "research_categories": "[\"Psychology\", \"Biological Psychology\"]",
                    "keywords": "",
                    "created_at": "2022-12-20T01:37:53+08:00"
                },
                "addressed_problems": [
                    {
                        "id": "paper:811894248839315456::problem",
                        "content": "Attention-deficit/hyperactivity disorder (ADHD) has been widely described as a childhood neuropsychiatric disorder whose core symptoms are often alleviated by psychostimulants, and this therapeutic response has been used to argue that ADHD reflects an underlying dopaminergic deficit of mainly genetic origin. The scientific problem is that this dopamine-deficit hypothesis has been treated as established even though the supporting evidence is fragmentary and methodologically indirect: neurochemical studies yield inconsistent findings on dopamine transporter function and extracellular dopamine tone; imaging studies using [11C]raclopride can be interpreted in more than one way and do not provide a clean measure of basal dopamine state; genetic associations with dopaminergic variants are statistically small and do not establish a strong causal link; pharmacological efficacy is confounded because psychostimulants also act through noradrenergic mechanisms and non-dopaminergic treatments can be equally effective; and animal models or brain-imaging abnormalities do not map straightforwardly onto a simple dopamine-deficit mechanism. As a result, the field lacks a robust basis for claiming that ADHD is a primary dopaminergic hypofunction disorder, and that uncertainty has consequences: it can bias interpretation of ADHD biology, overstate the explanatory power of dopamine-centered theories of reward, and preferentially frame psychostimulant medication as the scientifically privileged treatment despite limited evidence for long-term benefit on educational, behavioral, or substance-use outcomes.",
                        "keywords": [
                            "ADHD pathophysiology",
                            "dopamine-deficit hypothesis",
                            "psychostimulant treatment bias",
                            "neurochemical and genetic evidence",
                            "long-term outcomes"
                        ],
                        "metadata": {
                            "keywords": [
                                "ADHD pathophysiology",
                                "dopamine-deficit hypothesis",
                                "psychostimulant treatment bias",
                                "neurochemical and genetic evidence",
                                "long-term outcomes"
                            ]
                        }
                    }
                ],
                "open_questions": [
                    {
                        "id": "paper:811894248839315456::open_question",
                        "content": "The paper leaves unresolved what the most adequate non-dopaminergic or multicomponent biological account of ADHD should be, since no alternative theory has yet achieved general consensus. It also leaves open how the heterogeneous structural and functional brain abnormalities seen in ADHD relate to development, symptom expression, and treatment response, especially given the observation that ADHD may involve delay rather than deviance in cortical maturation. More broadly, the mechanistic role of dopamine in reward, motivation, and decision making remains debated in ways that continue to complicate attempts to connect neurobiology with ADHD symptoms and comorbidities. Finally, the long-term functional impact of stimulant medication remains uncertain enough that future work is needed to determine which interventions most effectively improve educational, behavioral, and social outcomes over time."
                    }
                ],
                "graph": {
                    "nodes": [
                        {